With a $372M megaround, Formation Bio looks to in-license 10+ drugs

Andrew Dunn

Senior Biopharma Correspondent

While the bulk of AI-focused biotechs try to discover drugs and push the boundaries of biology, Benjamine Liu would rather synthesize meeting minutes than molecules …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With a $372M megaround, Formation Bio looks to in-license 10+ drugs

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

Exclusive: J&J folds cardiovascular and metabolic drug unit

FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller

Novo Nordisk to decrease some insulin pen manufacturing, transition supply

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

With a $372M megaround, For­ma­tion Bio looks to in-li­cense 10+ drugs

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

FDA ap­proves Dupix­ent in COPD, open­ing ‘next chap­ter’ for Sanofi and Re­gen­eron’s best­seller

No­vo Nordisk to de­crease some in­sulin pen man­u­fac­tur­ing, tran­si­tion sup­ply

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

With a $372M megaround, Formation Bio looks to in-license 10+ drugs

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

Exclusive: J&J folds cardiovascular and metabolic drug unit

FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller

Novo Nordisk to decrease some insulin pen manufacturing, transition supply

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships